Abstract
BACKGROUND As of January 1, 2021, there have been 81,947,503 confirmed cases of COVID-19, resulting in 1,808,041 deaths worldwide. Several vaccines are now available for emergency use, but it will take many months to immunize the world’s population. There is a pressing need for outpatient treatment now. We reviewed the possible options
METHODS We reviewed up-to-date information from several sources to identify potential treatments to be utilized now for COVID-19. We searched for all ongoing, completed and published trial results with subject numbers of 100 or more, and used a targeted search to find announcements of unpublished trial results.
RESULTS As of December 27, 2020, we identified 750 trials currently in recruitment phase. Of these, 122 were directed at prevention in healthy individuals, 100 were classified as treatment of outpatients with documented infection, and 390 were for treatment of hospitalized inpatients. There were 9 trials focusing on the post discharge Tail phase. Among the trials, there were 60 vaccine trials, 120 trials of hydroxychloroquine, 33 trials of alternative therapy, 12 trials of colchicine, 38 trials of anticoagulants, 22 trials of the RNA polymerase inhibitor favipiravir (FVP), 19 trials of interferons, 18 trials of glucocorticoid, and 58 trials of plasma based products. Closure of enrollment was projected by the end of the year for 153 trials. We found 83 publications reporting findings in human studies on 14 classes of agents, and on 7 vaccines. There were 45 randomized or active controlled studies, the rest retrospective observational analyses. Most publications dealt with hospitalized patients, only 18 publications in outpatients. Remdesivir, convalescent plasma, and synthetic anti-spike protein antibodies have been granted emergency use authorization in the United States. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. There is data supporting the use of several antiviral medications, some of which are in use in other countries.
CONCLUSION Vaccines and antibodies are highly antigen specific. There is a need for antiviral agents in addition to mass immunization. It will be necessary for public health authorities to make hard decisions, with limited data, to prevent the continued spread of the disease and deaths.
Competing Interest Statement
Dr. Binh Ngo is a speaker for Castle Biosciences. Dr. Armstrong reports grants and personal fees from Abbvie, grants and personal fees from Bristol-Myers Squibb, personal fees from Dermavant, grants from Dermira, grants and personal fees from Eli Lilly, grants and personal fees from Janssen, grants from Kyowa Hakko Kirin, grants and personal fees from LEO Pharma, grants and personal fees from Modernizing Medicine, grants and personal fees from Novartis, personal fees from Ortho-Dermatologics, personal fees from Pfizer, grants and personal fees from Regeneron, personal fees from Sanofi-Genzyme, personal fees from Science 37, Inc, grants from UCB Biopharma Dr. Dube reports grants from Gilead Sciences, outside the submitted work; Dr. Chaudhary has held stock in Gilead Sciences, Roche Holding and Moderna. Dr. Piccirillo reports personal fees from Daichii Sankyo, personal fees from GSK, personal fees from MSD, grants from Roche, grants and personal fees from AstraZeneca, non-financial support from Bayer, outside the submitted work;. Dr. Mussini is member of a Roche Data Safety Monitoring Board for tocilizumab
Funding Statement
No external funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB needed for systematic analysis
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵1 From the Keck Medical School of USC
↵2 From the Rose Salter Medical Research Foundation
↵3 CoSenior author
mdube{at}med.usc.edu, Neha.nanda{at}med.usc.edu, Gino.In{at}med.usc.edu, arkfeld{at}med.usc.edu, Preet.chaudhary{at}med.usc.edu, campese{at}med.usc.edu, Diana.Hanna{at}med.usc.edu, David.sawcer{at}med.usc.edu, Glenn.ehresmann{at}med.usc.edu, David.Peng{at}med.usc.edu, smogorze{at}med.usc.edu, April.armstrong{at}med.usc.edu, ‘Dasgupta, Rajkumar’ rdasgupt{at}med.usc.edu, fsattler{at}usc.edu
updated as of January 1, 2021
Data Availability
We have provided a comprehensive list of all clinical trials with their registration as Supplementary Table 1 and all completed trials as Supplementary Table 2
